Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789256 · ClinicalTrials.gov registry record · NA
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
A NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT00789256: Completed NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00789256 is a NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 26 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00789256, a NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).
Primary Outcome
Determine disease response to treatment using Cheson 2000 report of an international working group to standardize response criteria for myelodysplastic syndromes.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Bortezomib
- DRUG Melphalan and bortezomib
Study Locations (2)
Florida
- Integrated Community Oncology Network - Jacksonville
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00789256 record still lists
NCT00789256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 3 interventions - of which Melphalan is the first listed.
NCT00789256 reports a single indexed study location in Florida, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00789256 about?
NCT00789256 is a clinical study titled "Low Dose Melphalan and Bortezomib for AML and High-Risk MDS". The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).
What is the current status of trial NCT00789256?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2004-09. Estimated completion is 2008-12.
What conditions does trial NCT00789256 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT00789256?
The interventions under investigation include: Melphalan (DRUG), Bortezomib (DRUG), Melphalan and bortezomib (DRUG).
Who is sponsoring clinical trial NCT00789256?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00789256 being conducted?
This trial has 2 study locations across Florida, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00789256's enrollment target sits among peer trials
26 127th of 173 higher than 46 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Home Blood Transfusions
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
RECRUITING · NA
-
Mosaic Trial for Stem Cell Transplant Recipients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia